Netherlands Liver Cancer Therapeutics Market Report 2022 to 2030

Netherlands Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Netherlands Liver Cancer Therapeutics market will reach a value of $28.8 Mn from $7.6 Mn in 2022, growing at a CAGR of 18.1 % during 2022-2030. The Liver Cancer Therapeutics in the Netherlands is dominated by a few domestic pharmaceutical companies such as AM-Pharma, Kiadis Pharma and Galapagos. The Liver Cancer Therapeutics market in the Netherlands is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Netherlands Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10NLPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Netherlands AUTHOR: Dr. Vishwa Modhia

Buy Now

Netherlands Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Netherlands Liver Cancer Therapeutics market will reach a value of $28.8 Mn from $7.6 Mn in 2022, growing at a CAGR of 18.1 % during 2022-2030.

The Netherlands is a high-income, developed constituent country located in Western Europe and with territories in the Caribbean. Liver cancer, also known as hepatocellular carcinoma (HCC), is a relatively rare form of cancer that affects the liver. In the Netherlands, liver cancer is estimated to be the 12th most common type of cancer in men and the 15th most common type of cancer in women. About 6.8% of the estimated cancers in the Netherlands, were liver cancers attributed to alcohol drinking.

According to the latest WHO data published in 2020 Liver Cancer Deaths in the Netherlands reached 1,163 or 0.92% of total deaths. The age-adjusted Death Rate is 3.18 per 100,000 population ranks Netherlands #160 in the world. Netherlands’ government spent 11.1 % of its GDP on healthcare in 2020.

Netherlands Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Collaboration and collaborations between healthcare providers, research institutions, and pharmaceutical companies may result in the development of novel treatments and technology, accelerating the growth of the Dutch liver cancer market. Rotterdam, Netherlands, is Europe's leading port, making business transactions easier. The excellent quality infrastructure and living standards in the Netherlands are a plus. These aspects could boost the Netherlands Liver Cancer Therapeutics market.

Market Restraints

Patients with liver cancer in the Netherlands may be able to participate in clinical trials for experimental treatments in addition to established treatments such as surgery, radiation therapy, and chemotherapy. Participating in a clinical study may provide access to therapies that are not yet generally available, but it may also come with additional fees or hazards. The incidence of liver cancer in the Netherlands has increased in recent years, but it remains low in comparison to other nations. The pension system in the Netherlands is under strain as the population ages. These factors may deter new entrants into the Netherlands Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

AM-Pharma: This is a Dutch biopharmaceutical company that develops drugs for the treatment of inflammatory and kidney diseases. The company has a pipeline of products in development for the treatment of liver diseases, including liver cancer
Kiadis Pharma: This is a Dutch biopharmaceutical company that develops drugs for the treatment of cancer and blood disorders
Galapagos NV: This is a Dutch biotechnology company that develops drugs for the treatment of inflammatory and fibrotic diseases
Merus NV: This is a Dutch clinical-stage biopharmaceutical company that develops bispecific antibodies for the treatment of cancer
Lead Pharma: This is a Dutch pharmaceutical company that develops drugs for the treatment of immune-related diseases and cancer

Recent Notable Updates

April 2021: Sanofi and Kiadis announced the completion of Sanofi's acquisition of Kiadis, a clinical-stage biopharmaceutical firm developing next-generation, "off-the-shelf" NK cell therapeutics. Kiadis' patented platform is built on allogeneic (from a healthy donor) NK cells. NK cells search for and identify malignant cancer cells and have a wide range of applications in a variety of tumour types. The technology has the potential to make treatments quickly and affordably available to a large patient population with a variety of liquid and solid malignancies, as well as to generate synergies with Sanofi's immuno-oncology programme. Kiadis' NK cell-based treatments will be developed both independently and in collaboration with Sanofi's current pipeline and platforms.

Healthcare Policies and Reimbursement Scenarios

The treatment of liver cancer in the Netherlands is controlled and compensated through the Dutch healthcare system. The Dutch healthcare system is built on a mandated health insurance system, with all citizens having to obtain coverage. In the Netherlands, liver cancer treatment is usually covered by health insurance, though the extent of coverage varies depending on criteria such as the type of treatment, the patient's insurance plan, and the availability of alternative treatments. The Dutch healthcare system is based on a reimbursement model, with health insurers paying healthcare providers for the services they perform.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.